Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

SweetSpot - Effekten af ikke-nærende sødemidler på sundheden

5. november 2026 opdateret af: Monica Mars, Wageningen University

SweetSpot - Effekten af ikke-nærende sødestoffer på glukoseregulering, tarmmikrobiom og tarmhormonsekretion hos raske voksne: et fuldt kontrolleret krydset interventionsstudie

The aim of the study is to investigate the effect of non-nutritive sweeteners on glucose regulation. Secondary objectives are to investigate the effect of NNS on gut microbiome, gut hormone secretion, sweet taste sensitivity and preference, and the excretion of NNS in urine.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Sugar intake has increased over the years, simultaneously with the prevalence of overweight and obesity. To decrease sugar intake, consumption of non-nutritive sweeteners (NNS) has increased and opinions on its use remain divided. A fully controlled dietary intervention using a NNS mixture and dose that is similar to real-life intake, is therefore necessary to advance our understanding of the potential effects of NNS on glucose regulation, gut microbiome, and gut hormone secretion under real-life conditions.

The aim of this study is to investigate the effect of non-nutritive sweeteners on glucose regulation. Secondary objectives are to investigate the effect of NNS on gut microbiome, gut hormone secretion, sweet taste sensitivity and preference, and the excretion of NNS in urine.

To do this, a single blind, fully controlled dietary intervention with a cross-over design will be performed. The study will consist of 2x8 weeks of intervention, with a washout of > 6 weeks in between. The study population will be 60 healthy adults aged 45-79, with a BMI between 20-35 kg/m2.

The study will consist of a fully controlled diet of two 8-week intervention periods (2 weeks run-in + 6 weeks intervention). The diets differ in the presence of non-nutritive sweeteners (NNS): NNS-diet versus non-NNS diet, where additional NNS are added to the NNS-diet.

The primary outcome measure will be the within person difference in blood glucose incremental area under the curve following a 75 g glucose tolerance test between the NNS diet and the non-NNS diet. Secondary outcome measures are the effect of NNS on Matsuda index, insulin response, blood lipid profile, and gut hormone secretion will be determined. The effect of NNS on small- and large intestinal microbiome will be investigated by a change in composition, functionality, and short chain fatty acid content. The effect of NNS on sweet taste sensitivity, preference, and liking will be investigated, as well as the excretion of NNS in urine and saliva.

The total time invested by participants is around 85 hours. Participants are restricted for 16 weeks in their eating habits, since they follow a fully controlled diet prepared by the research facility. Participants will visit the research facility in total 38 times. In total, ~ 603 mL of blood will be drawn by experienced nurses over the entire RCT (>6 month period). During DEXA scans, participants will receive a total of about 0.006 mSv of radiation.

Invasive measurements that participants can experience as burden are collection of faecal and urine samples, and finding back the Simba capsules in the stool. Non-invasive measurements for participants are wearing the CGM, wearing the ActiGraph, consuming the blue cakes, and performing sensory tests.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

60

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Gelderland
      • Wageningen, Gelderland, Holland, 6708WG
        • Wageningen University & Research

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

45 år til 79 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age 45-79 years;
  • BMI of 20-35 kg/m2;
  • Having veins suitable for placement of a venflon catheter.

Exclusion Criteria:

  • Diseases or prior surgeries affecting the stomach, liver, kidneys or intestines (allowed i.e. appendectomy);
  • Cardiovascular diseases (e.g. heart failure) or cancer (e.g. non-invasive skin cancer allowed);
  • Diagnosed with type 1 or type 2 diabetes;
  • Drug treated thyroid diseases (well substituted hypothyroidism is allowed for inclusion);
  • HbA1c level >6.5% (>48 mmol/mol), as measured during the screening visit;
  • Anaemia defined as Hb concentrations <8.5 mmol/L for men and <7.5 mmol/L for women via finger prick;
  • Regular use of/receiving medication interfering with research outcomes (as judged by research physician), such as use of glucose lowering drugs, insulin, or use of medication that impacts the gastro-intestinal system;
  • Use of antibiotics over the last 3 months before study start;
  • Donated blood within 2 months prior to the screening;
  • Food allergies, intolerances (including lactose/gluten intolerance) for products used in the study design and/or dietary restrictions interfering with the study (including special diets and eating disorders);
  • Followed a diet that can interfere with the study outcomes within 1 month prior to the screening (e.g. ketogenic, sugar free, carbohydrate free);
  • Not willing to eat all products in the study diet, including eggs and dairy. Vegetarian is possible;
  • Not willing to consume non-nutritive sweeteners;
  • Not willing to quit the use of supplements that can interfere with the study outcomes (e.g. pre- or probiotics).
  • Intention to change the intensity of exercise during the study period or planning to join a intensive sport event (e.g. marathon or triathlon);
  • Intention to lose or gain weight;
  • Working night shifts regularly;
  • Smoking regularly
  • Use of soft and/or hard drugs (cannabis included);
  • Abuse of alcohol (defined as >14 glasses (women) or >21 glasses (men) of alcoholic beverages per week);
  • Being pregnant or lactating or planning to become pregnant;
  • Inability to understand study information and/or communicate with staff;
  • Participation in another study that involves an intervention within two months prior to the intervention;
  • Working or doing a thesis/internship at the division of Human Nutrition & Health, or the Food, Health & Consumer Research group of Wageningen Food & Biobased Research.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Andet
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Andet: NNS / no-NNS

In this arm, participants will first receive the NNS diet, and the no-NNS diet in the second study period.

Fully controlled diet with added mixture of non-nutritive sweeteners. The mixture consist of 6 different non-nutritive sweeteners: acesulfame-K, aspartame, cyclamate, saccharin, sucralose, and rebaudioside A (stevia).

Fully controlled diet without any non-nutritive sweeteners added.

Andet: No-NNS / NNS

In this arm, participants will first receive the no-NNS diet, and the NNS diet in the second study period.

Fully controlled diet with added mixture of non-nutritive sweeteners. The mixture consist of 6 different non-nutritive sweeteners: acesulfame-K, aspartame, cyclamate, saccharin, sucralose, and rebaudioside A (stevia).

Fully controlled diet without any non-nutritive sweeteners added.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Difference in change in 2h iAUC glucose after 6 weeks between the intervention and the control.
Tidsramme: Week 2 and week 8 in both intervention periods (4 times in total)

The primary outcome measure is the difference in change in iAUC of blood glucose levels following a 2-hour oral glucose tolerance test (OGTT) after six weeks between the intervention period and the control period.

Week 2 and week 8 in both intervention periods (4 times in total)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Matsuda index
Tidsramme: Week 2 and week 8 in both intervention periods (4 times in total)

Matsuda index after an OGTT

Week 2 and week 8 in both intervention periods (4 times in total)
Fasting blood glucose
Tidsramme: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Fasting blood glucose

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Fasting blood insulin
Tidsramme: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Fasting blood insulin

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Postprandial insulin response
Tidsramme: Week 2 and 8 in both intervention periods (4 times in total).

2-hour iAUC blood insulin during OGTT

Week 2 and 8 in both intervention periods (4 times in total).
Postprandial glucose response after a breakfast
Tidsramme: Week 7 in both study periods (2 times in total)

Postprandial blood glucose responses (PPGR) following specific meals measured by CGM.

Week 7 in both study periods (2 times in total)
Blood lipid profile
Tidsramme: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

All circulating blood lipids, including all cholesterol types, triglycerides, and free fatty acids (FFAs).

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Gut microbiota composition
Tidsramme: Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.

Microbiota composition in faeces

Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
Gut microbiota function
Tidsramme: Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.

Microbiota functionality measured in faeces

Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
Microbial metabolites
Tidsramme: Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.

Microbial metabolites measured in faeces

Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
Small intestinal microbiota composition
Tidsramme: Week 7 of both intervention periods (2 times in total).

Microbiota composition of the small intestine measured with Simba Capsules

Week 7 of both intervention periods (2 times in total).
Gastro-intestinal transit time
Tidsramme: Baseline & week 7 of both intervention periods (3 times in total).

Gastro-intestinal transit time measured with blue muffins.

Baseline & week 7 of both intervention periods (3 times in total).
Oral microbiome composition & function
Tidsramme: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Oral microbiome composition & function measured in saliva

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Postprandial GLP-1 secretion
Tidsramme: Week 2 and 8 of both intervention periods (4 times in total).

3-hour AUC of GLP-1 during an OGTT.

Week 2 and 8 of both intervention periods (4 times in total).
Postprandial GIP secretion
Tidsramme: Week 2 and 8 of both intervention periods (4 times in total).

3-hour AUC of GIP during an OGTT.

Week 2 and 8 of both intervention periods (4 times in total).
Sweetness-liker phenotype
Tidsramme: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Sweetness-liker phenotype, with the sweetness liker test.

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Sweetness preference & liking
Tidsramme: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Sweetness preference & liking measured on a rank-rating scale. Preference will be determined using the categorical values from the rank-rating scale (1-5), and liking will be determined using the continuous values from the rank-rating scale (0-100).

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Sweet taste sensitivity
Tidsramme: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Sweet taste sensitivity measured on a 100mm Visual Analogue Scale. A higher score for all solutions indicates a higher sweet taste sensitivity.

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Excretion of NNS in urine
Tidsramme: Baseline, week 2 and week 8 in intervention period 1, and every two weeks in intervention period 2 (7 times in total).

Excretion of NNS in urine

Baseline, week 2 and week 8 in intervention period 1, and every two weeks in intervention period 2 (7 times in total).
Excretion of NNS in saliva
Tidsramme: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Excretion of NNS in saliva

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Anthropometrics
Tidsramme: Baseline

Measured as weight (kg), height (m), waist circumference (cm), and hip circumference (cm). Weight and height will be combined to report BMI in kg/m^2.

Baseline
Body composition
Tidsramme: Baseline & week 8 of both intervention periods (3 times in total).

Body composition as measured by DEXA (Dual Energy X-ray Absorptiometry).

Baseline & week 8 of both intervention periods (3 times in total).
Habitual food intake
Tidsramme: Baseline

Habitual dietary intake assessment with a food frequency questionnaire (FFQ).

Baseline
Physical activity level
Tidsramme: Baseline.

Physical activity level by the Short Questionnaire to Assess Health-enhancing physical activity (SQUASH).

Baseline.
Habitual NNS consumption
Tidsramme: Baseline

Habitual NNS consumption by questionnaire

Baseline
Gastro-intestinal symptoms
Tidsramme: Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.

Gastro-intestinal symptoms by GSRS questionnaire.

Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
Satiety
Tidsramme: Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.

Satiety questionnaire, adapted from the Control of Eating Questionnaire.

Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
Genetic variation
Tidsramme: Baseline

Single Nucleotide Polymorphisms (SNPs) in genes relevant collected using buffycoat.

Baseline
Taste function
Tidsramme: Baseline

Measure the ability to recognize the basic tastes in different concentrations, assessed with validated Taste Strips.

Baseline

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

23. februar 2026

Primær færdiggørelse (Anslået)

26. marts 2027

Studieafslutning (Anslået)

26. marts 2027

Datoer for studieregistrering

Først indsendt

13. januar 2026

Først indsendt, der opfyldte QC-kriterier

13. januar 2026

Først opslået (Faktiske)

23. januar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • NL010297

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .